Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx (NASDAQ:RARE) and Tonix Pharma (NASDAQ:TNXP).
Ultragenyx (RARE)
JMP Securities analyst Liisa Bayko reiterated a Buy rating on Ultragenyx on August 28 and set a price target of $94. The company’s shares closed on Friday at $84.73, close to its 52-week high of $87.33.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 22.6% and a 52.2% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, DBV Technologies SA – American, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx with a $91.60 average price target, an 8.1% upside from current levels. In a report issued on August 17, SunTrust Robinson also reiterated a Buy rating on the stock with a $83 price target.
.
See today’s analyst top recommended stocks >>
Tonix Pharma (TNXP)
CIM Securities analyst Kumaraguru Raja maintained a Hold rating on Tonix Pharma on August 30. The company’s shares closed on Friday at $1.07, close to its 52-week low of $0.89.
According to TipRanks.com, Raja is ranked #3743 out of 4876 analysts.
Tonix Pharma has an analyst consensus of Hold, with a price target consensus of $1.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
